UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE TO

(Amendment No. 1)

TENDER OFFER STATEMENT

UNDER SECTION 14(D)(1) OR SECTION 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

VNUS MEDICAL TECHNOLOGIES, INC.

(Name Of Subject Company (Issuer))

COVIDIEN GROUP S.A.R.L.

COVIDIEN DELAWARE CORP.

(Names of Filing Persons (Offerors))

Common Stock, par value $0.001 per share

(Title of Class of Securities)

928566108

(CUSIP Number of Common Stock)

 

 

Michelangelo Stefani

Covidien Group S.a.r.l.

3b Bld Prince Henri

L-1724, Luxembourg

Telephone: +352 266 379 31

(Name, address and telephone number of person authorized

to receive notices and communications on behalf of filing persons)

with copies to:

Paul Kinsella

Ropes & Gray LLP

One International Place

Boston, Massachusetts 02110

Telephone: (617) 951-7000

CALCULATION OF FILING FEE

 

Transaction Valuation*

   Amount Of Filing Fee**

$522,472,033

   $29,154

 

* Estimated solely for purposes of calculating amount of filing fee in accordance with Rule 0-11 under the Securities Exchange Act of 1934. The transaction value is based upon the offer to purchase 18,016,277 outstanding shares of Common Stock of VNUS Medical Technologies, Inc. at a purchase price of $29.00 cash per share. Such number of outstanding shares of Common Stock represents the total of 16,234,156 issued and outstanding shares of Common Stock, outstanding options with respect to 1,063,784 shares of Common Stock and restricted stock units with respect to 718,337 shares of Common Stock, in each case as of May 13, 2009.

 

** The amount of filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 5 for fiscal year 2009 issued by the Securities and Exchange Commission. Such fee equals .00558% of the transaction value.

 

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

 

Amount Previously Paid:

   $29,154

Form or Registration No.:

   Schedule TO-T

Filing Party:

   Covidien Group S.a.r.l.

Date Filed:

   May 18, 2009

 

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

x third-party tender offer subject to Rule 14d-1.

 

¨ issuer tender offer subject to Rule 13e-4.

 

¨ going-private transaction subject to Rule 13e-3.

 

¨ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:    ¨

 

 

This Amendment No. 1 to the Tender Offer Statement on Schedule TO (this “ Amendment ”), filed with the Securities and Exchange Commission on May 28, 2009, amends and supplements the Tender Offer Statement on Schedule TO filed on May 18, 2009 (the “ Schedule TO ”) and relates to a tender offer by Covidien Delaware Corp., a Delaware corporation (the “ Offeror ”) and a wholly owned subsidiary of Covidien Group S.a.r.l., a Luxembourg company (“ Parent ”), to purchase all of the outstanding shares of Common Stock, par value $0.001 per share (the “ Shares” ), of VNUS Medical Technologies, Inc., a Delaware corporation (the “ Company ”), at a purchase price of $29.00 per Share, net to the seller in cash, without interest thereon, less any applicable withholding taxes, and subject to the conditions set forth in the Offer to Purchase for Cash dated May 18, 2009 (the “ Offer to Purchase ”) and in the related Letter of Transmittal (the “ Letter of Transmittal ” which, together with the Offer to Purchase, as each may be amended and supplemented from time to time, constitute the “ Offer ”). This Amendment is being filed on behalf of the Offeror and Parent.

The information set forth in the Offer to Purchase and the Letter of Transmittal, copies of which are filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively, is incorporated by reference in answers to Items 1 through 9 and Item 11 of the Schedule TO, and is supplemented by the information specifically provided herein.

 

ITEM 11. ADDITIONAL INFORMATION

The Schedule TO is hereby amended and supplemented by adding the following to Sections (a)(2) and (a)(3) of Item 11:

On May 12, 2009, Covidien Ltd., the parent company of Parent and the Offeror, and the Company each filed a Premerger Notification and Report Form with respect to the Offer with the Antitrust Division of the Department of Justice and the Federal Trade Commission (the “ FTC ”) in accordance with the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “ HSR Act ”).

At 11:59 p.m., New York City time, on May 27, 2009, the HSR Act waiting period with respect to the Offer and Merger expired. Accordingly, the condition to the Offer that any waiting period under the HSR Act shall have expired or been terminated has been satisfied.

ITEM 12. EXHIBITS

 

(a)(1)(A)

   Offer to Purchase for Cash, dated May 18, 2009.*

(a)(1)(B)

   Form of Letter of Transmittal.*

(a)(1)(C)

   Form of Notice of Guaranteed Delivery.*

(a)(1)(D)

   Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

(a)(1)(E)

   Form of Letter to Clients for Use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

(a)(2)

   None.

(a)(3)

   None.

(a)(4)

   None.

(a)(5)(A)

   Joint Press Release issued by Covidien Ltd. and VNUS Medical Technologies, Inc., dated May 8, 2009 (incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Covidien Ltd. on May 8, 2009).*

(a)(5)(B)

   Summary Advertisement published in the Wall Street Journal on May 18, 2009.*

(b)

   None.

(d)(1)

   Agreement and Plan of Merger, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and VNUS Medical Technologies, Inc.*

(d)(2)

   Form of Tender and Voting Agreement, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and certain shareholders of VNUS Medical Technologies, Inc. *

(d)(3)

   Confidentiality and Standstill Agreement, dated as of February 3, 2009, by and between Tyco Healthcare Group LP and VNUS Medical Technologies, Inc.*

(d)(4)

   Guaranty, dated as of May 7, 2009, by Covidien International Finance S.A.*

(g)

   None.

(h)

   None.

 

* Previously filed

SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

    COVIDIEN GROUP S.A.R.L.
Dated: May 28, 2009     By:   / S / M ICHELANGELO F. S TEFANI
      Name:   Michelangelo F. Stefani
      Title:   General Manager

 

    COVIDIEN DELAWARE CORP.
Dated: May 28, 2009     By:   / S / J OHN W. K APPLES
      Name:   John W. Kapples
      Title:   Vice President and Secretary

EXHIBIT INDEX

 

(a)(1)(A)

   Offer to Purchase for Cash, dated May 18, 2009.*

(a)(1)(B)

   Form of Letter of Transmittal.*

(a)(1)(C)

   Form of Notice of Guaranteed Delivery.*

(a)(1)(D)

   Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

(a)(1)(E)

   Form of Letter to Clients for Use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

(a)(2)

   None.

(a)(3)

   None.

(a)(4)

   None.

(a)(5)(A)

   Joint Press Release issued by Covidien Ltd. and VNUS Medical Technologies, Inc., dated May 8, 2009 (incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Covidien Ltd. on May 8, 2009).*

(a)(5)(B)

   Summary Advertisement published in the Wall Street Journal on May 18, 2009.*

(b)

   None.

(d)(1)

   Agreement and Plan of Merger, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and VNUS Medical Technologies, Inc.*

(d)(2)

   Form of Tender and Voting Agreement, dated as of May 7, 2009, by and between Covidien Group S.a.r.l., Covidien Delaware Corp. and certain shareholders of VNUS Medical Technologies, Inc.*

(d)(3)

   Confidentiality and Standstill Agreement, dated as of February 3, 2009, by and between Tyco Healthcare Group LP and VNUS Medical Technologies, Inc.*

(d)(4)

   Guaranty, dated as of May 7, 2009, by Covidien International Finance S.A.*

(g)

   None.

(h)

   None.

 

* Previously Filed
Vnus Medical Technologies (MM) (NASDAQ:VNUS)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Vnus Medical Technologies (MM) Charts.
Vnus Medical Technologies (MM) (NASDAQ:VNUS)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Vnus Medical Technologies (MM) Charts.